Status:
TERMINATED
The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Middle Cerebral Artery Stroke
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The safety and efficacy of MK0724 will be assessed in patients with acute middle cerebral artery stroke using the Action Reach Arm Test (ARAT). This test allows measurement of a specific functional de...
Eligibility Criteria
Inclusion
- 18-80 yrs of age inclusive
- Patient is able to receive IV infusion 8-36 hours after stroke onset
- Baseline NIHSS of 6-18 inclusive
Exclusion
- Patient had another stroke within 3 months preceding current stroke, patient's stroke is of origin other than MCA (e.g., non-ischemic, hemorrhage), significant cerebral edema, abnormal liver enzymes and abnormal renal and hepatic functions
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00401310
Start Date
July 1 2007
End Date
January 1 2009
Last Update
July 22 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.